Conclusion: All antidepressants were more efficacious than placebo in adults with major depressive disorder. Smaller differences between active drugs were found when placebo-controlled trials were included in the analysis, whereas there was more variability in efficacy and acceptability in head-to-head trials. These results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers on the relative merits of the different antidepressants.
PubMed 29477251 ↗Escitalopram
Also known as Lexapro, Cipralex
The short answer. People are split on Escitalopram — 41% of 82 say it helped. It is most often used for mood: 80% of 44 reports say that improved. It is well studied — 219 meta-analyses on PubMed. The most common complaint is emotional blunting.
From 135 mentions in total — the rest didn't say how it went and aren't counted.
What Escitalopram does, according to users
Of the people who reported each effect, the share who said it got better.
4 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 219 meta-analyses on PubMed ↗ · 659 randomized trials ↗
Conclusion: To our knowledge, this is the largest contemporary review of pharmacological agents for the treatment of generalised anxiety disorder by use of network analysis. There are several effective treatment choices for generalised anxiety disorder across classes of medication. The failure of initial pharmacological therapy might not be a reason to abandon a pharmacological treatment strategy.
PubMed 30712879 ↗Conclusion: Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had reasonable efficacy, acceptability, and tolerability in the treatment of adults with stable MDD.
PubMed 36253442 ↗Conclusion: Escitalopram was superior to other ADs for the acute phase treatment of MDD in terms of efficacy, acceptability and tolerability. However, no significant difference was found between escitalopram and other ADs in early response or follow-up response to treatment of MDD.
PubMed 38001423 ↗725 human trials on ClinicalTrials.gov test Escitalopram — 474 completed, 34 recruiting now. See all on ClinicalTrials.gov ↗
- Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant · Depression, Anxiety · 2026
- Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants · Depression, Inflammation · 2026
- Treating Negative Affect in Low Back Pain Patients · Chronic Low Back Pain, Negative Affectivity · 2024
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Boxed warning (the FDA's strongest label warning): “SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.…”
2 recalls of products named for Escitalopram. Most recent:
- 2016-09-28 · Class III: Labeling: Incorrect or Missing Lot and/or Expiration Date record ↗
- 2014-01-29 · Class II: Labeling: Label Mixup: ESCITALOPRAM, Tablet, 5 mgmay have potentially been mislabeled as the following drug: SODIUM CHLORIDE, Tablet, 1 gm, NDC 00223176001,… record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
139,496 adverse-event reports mention Escitalopram. Most often reported:
- Fatigue · 9,541
- Nausea · 9,519
- Drug ineffective · 8,998
- Headache · 7,397
- Diarrhoea · 7,046
- Anxiety · 6,668
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
NIH has funded 14 research projects with Escitalopram in the title, $24,756,584 in total (2002–2025). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Escitalopram ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“Escitalopram is what makes me feel normal, i react to it very quickly too, but it seems to induce hypomania on first days of intake. Brings me back confidence, ambition, motivation, energy, relieves anxiety, kicks depression.”
“I was on it for 7 months and improved my mood and lowered my anxiety. But it also made me apathetic/unmotivated, caused emotional blunting and sexual dysfunction.”
“I've had a positive outcome, have no more anxiety, and these personality changes are welcomed.”
“I started lexapro last year and it changed my life for the better.”
Top discussions (5)
Escitalopram compared
Other options for mood
Sources
- User reports: 135 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate